Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Experts say a healthy vaginal microbiome may cut down one's risk of infections like HPV in check. Probiotics can balance pH, ...
It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor tissue penetration and off-target toxicity. These drawbacks can prevent complete ...
Using a new technology and computational method, researchers from Fred Hutch Cancer Center and The University of Texas MD ...
Cervical cancer begins in the epithelial cells of the cervix following an ongoing period of infection with high-risk types of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results